Oxybutynin, tolterodine, and darifenacin: review of cognitive adverse events
Boudreau R, Cimon K, Cunningham J
Record ID 32011001211
English
Authors' recommendations:
Most of the studies concluded that cognitive function was not affected by taking oxybutynin, tolterodine, or darifenacin. All of the studies were short-term which may not reflect the typical patient on these medications. Three FDA advisories have been issued which stated that there have been reports of cognitive adverse events like confusion in the post-market use of oxybutynin, tolterodine, and darifenacin. These reports do not contain enough data to determine meaningful information such as cognitive adverse event rates. It has been postulated that certain populations, such as older adults, may be less suitable candidates for oxybutynin, tolterodine, or darifenacin. Elderly patients are often taking multiple prescriptions which can increase the possibility of experiencing a drug to drug interaction and if those drugs have anticholinergic properties then the probability of cognitive impairment and other anticholinergic-associated adverse events may be higher. Given the lack of longer-term trials of oxybutynin, tolterodine, and darifenacin, it is unknown whether the longer-term use of these medications for chronic issues such as OAB negatively affects the cognitive function of patients. In addition, trials designed specifically to compare the cognitive adverse events of oxybutynin, tolterodine, and darifenacin were not identified.
Details
Project Status:
Completed
Year Published:
2009
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Canada
MeSH Terms
- Muscarinic Antagonists
- Pyrrolidines
Contact
Organisation Name:
Canadian Agency for Drugs and Technologies in Health
Contact Address:
600-865 Carling Avenue, Ottawa, ON K1S 5S8 Canada. Tel: +1 613 226 2553; Fax: +1 613 226 5392;
Contact Name:
requests@cadth.ca
Contact Email:
requests@cadth.ca
Copyright:
Canadian Agency for Drugs and Technologies in Health (CADTH)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.